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The basis of Haemophilus inﬂuenzae type b (Hib) and Neisseria meningitidis serogroup C (MenC) glyco-
conjugates binding to aluminum-containing adjuvants was studied. By measuring the amount of poly-
saccharide and protein in the non-adsorbed supernatant, the adjuvant, aluminum phosphate, AlPO4, was
found to be less efﬁcient than aluminum hydroxide, Al(OH)3 at binding to the conjugates, at concentrations
relevant to licensed vaccine formulations and when equimolar. At neutral pH, binding of TT conjugates to
AlPO4 was facilitated through the carrier protein, with only weak binding of AlPO4 to CRM197 being observed.
There was slightly higher binding of either adjuvant to tetanus toxoid conjugates, than to CRM197 conjugates.
This was veriﬁed in AlPO4 formulations containing DTwPeHib, where the adsorption of TT-conjugated Hib
was higher than CRM197-conjugated Hib. At neutral pH, the anionic Hib and MenC polysaccharides did not
appreciably bind to AlPO4, but did bind to Al(OH)3, due to electrostatic interactions. Phosphate ions reduced
the binding of the conjugates to the adjuvants. These patterns of adjuvant adsorption can form the basis for
future formulation studies with individual and combination vaccines containing saccharide-protein
conjugates.
Crown Copyright © 2015 Published by Elsevier Ltd on behalf of The International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Aluminum-containing adjuvants have been successfully used since
the 1920s to stimulate the immune response to the relatively more
puriﬁed diphtheria toxoid (DT) and tetanus toxoid (TT) vaccine anti-
gens (Ags) being prepared at that time [1e4]. An understanding of the
mechanism(s) of action and the physical nature of the adjuvant-Ag
interactions leading to an enhanced immune response followingmaterial; Hib, Haemophilus
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es/by-nc-nd/4.0/).vaccine administration have only more recently been recognized
[5e9].
The most commonly used aluminum-containing adjuvants in
vaccines have been aluminum phosphate, AlPO4, and aluminum hy-
droxide, Al(OH)3, which have very different structural properties in
terms of their size, molecular organization, colloidal properties, and
solubility [6,10e12]. The binding or adsorption of protein antigens to
aluminum adjuvants occurs principally through electrostatic in-
teractions (involving the Al3þ ion or negatively-charged counter ion)
[12] as well as metal ion coordination and hydrogen bonding with
watermolecules and hydroxyl groups [10,11,13]; there is also evidence
that hydrophobic interactions are involved in some cases [14]. The
large surface area of these colloidal gel adjuvants, and size of the
particles (1e100 mm in diameter) also contributes to their adsorption
[6,12,15]. Aluminum hydroxide has an isoelectric point (pI) of >7.3 to
11.4 [6,12], while AlPO4 with a pI ofy4, binds primarily to positively
charged proteins and molecules [12].
Large aluminum adjuvant-Ag complexes of >0.2 mm shown to be
efﬁciently phagocytosedbyantigenpresenting cells [5,16], act as slow-
releasing local depots for a longer term re-exposure to Ag [17,18], and
lead to innate signaling that causes low-grade inﬂammation toal Alliance for Biological Standardization. This is an open access article under the CC
Table 1
Aluminum adjuvant concentrations in licensed conjugate vaccines.
Vaccinea Adjuvant [Adjuvant], mg Al3þ/mlb
Hib-CRM197 Bc,d AlPO4 0.6
MenA-TT AlPO4 0.6
MenC-CRM197 B AlPO4 0.25
Pneumo-CRM197 AlPO4 0.25
Pneumo-TT AlPO4 1.0
DTaP5Hib AlPO4 0.66
DTwP (HepB)Hibe AlPO4 0.6e0.7
Hib-OMPC Al(OH)3 0.44
MenC-CRM197 A Al(OH)3 0.7
MenC-TT Al(OH)3 1.0
DTaP3Hib Al(OH)3 1.0
DTwPHib Al(OH)3 0.8
a The following vaccines do not contain any aluminum adjuvant: Hib-CRM197 A,
Hib-TT, Men ACWY-CRM197, MenACWY-DT, MenACWY-TT. Hib-CRM197 and MenC-
CRM197 letter code designations are according to [39] and [40], respectively.
b Adjuvant concentrations were calculated from dose equivalent values given in
the publically accessible Summary of Product Characteristics for each product. For
lyophilised vaccines, the concentration is that obtained following reconstitution in
its diluent.
c A dash (-) sign is used between PS and carrier protein in conjugate vaccines.
d Those vaccines in bold font have been used in this study.
e According to the list of WHO Pre-qualiﬁed vaccines [69].
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which are separate means of stimulating T-cell help in the overall
production of neutralizing and protective antibodies. Studies have
shown that immunopotentiation can occur without adsorption or
depot formation at the inoculation site [8,21].
The modern development of adjuvant-containing vaccines in-
volves identifying the adjuvant beneﬁt in preclinical immunogenicity
studies, assessing its safety proﬁle in non-clinical toxicity studies and
assuring that the adjuvant formulation is stable with its adsorption to
Ag consistently controlled throughout the shelf-life of the product
[22e24]. Product-speciﬁcminimum andmaximum limits of adjuvant
adsorption should be established based on the level of adsorption of
the vaccines used in clinical trials. Minimum adsorption levels appli-
cable to all vaccines are no longer applicable, as complete adsorption
of the Ags to adjuvant may not be considered necessary or ideal
[25e28], and partial adsorption or associationmay be preferable [8,9].
The stability of the adjuvant formulation is also important with
respect to maintaining a consistent adsorption level throughout its
shelf-life, and avoiding any adverse effects on the vaccine [9,29,30].
The lot release of vaccines by manufacturers, as well as control labo-
ratories, in some cases, involves assessing the adjuvant material in
context of the vaccine Ag(s) [25,27]. This can involve quality control
tests of the bulk adjuvant material, such as purity, content, pH, and
adsorptive capacity, as well as a measure of the adsorption of Ag to
adjuvant in formulated vaccine.
In glycoconjugate vaccines, the bacterial oligo- or polysaccharide
target Ag is covalently coupled to a carrier protein such as TT, diph-
theria toxoid or a non-toxic genetic mutant of diphtheria toxin,
CRM197 [31], recombinant exotoxin A from Pseudomonas aeruginosa,
recombinant Protein D from non-typeable Haemophilus inﬂuenzae or
outermembrane protein complex fromNeisseriameningitidis group B.
While the carrier protein already acts as an ‘intrinsic’ adjuvant to
provide T-cell help in the immune response to the weaker T-inde-
pendent polysaccharide epitope [18], there can be additional beneﬁts
from the inclusion of aluminum adjuvants. When a glycoconjugate is
administered simultaneously or in combination with more immu-
nodominant Ags which may potentially interfere with the protective
response to the bacterial polysaccharide capsule, an adjuvant may
provide the immune stimulus to aid the production of high levels of
circulating antibodies and the formation of long-lived CD27þ IgGþ
memory cell pools.
Although the ﬁrst licensed monovalent H. inﬂuenzae type b
(Hib) conjugate vaccines were not formulated with aluminum
adjuvants, adjuvants were added to subsequent pneumococcal
and meningococcal group C conjugate (MenC) vaccines to boost
the production of polysaccharide-capsule speciﬁc bactericidal
antibodies (Table 1). Current DTP combinations that include Hib
conjugates contain aluminum adjuvants which may adsorb the
Hib conjugate component through ionic bonding. In clinical and
post-licensure studies, the immune response to some conjugate
vaccines has been found to be less efﬁcacious in the presence of
other more dominant Ags present in combination or concurrently-
administered vaccines [32,33]. Limited persistence of serum levels
of bactericidal antibodies to Hib and serogroup C meningococcus
[36e38] has led to the introduction of a booster dose of Hib and
MenC conjugates at 12 months in the U.K. The interactions of
saccharide-protein conjugates with adjuvants remain an important
but rather poorly understood area despite their common and
widespread use.
The aims of this study were to characterize the binding of the
individual saccharide and protein components of Hib and MenC
vaccines to aluminum adjuvants at physiological pH and ionic
strength, and under the formulation conditions of commercial
vaccines routinely given to infants in Europe and other parts of the
world. The effect of carrier protein and buffer salts, in particular,phosphate ions, was studied. The stability of MenC conjugate vac-
cines in context of adjuvant adsorption was also evaluated.2. Materials and methods
2.1. Vaccines and components
The Hib conjugate and MenC bulk conjugate vaccine compo-
nents used in this study consisted of a capsular oligo- or poly-
saccharide conjugated to either CRM197, the diphtheria toxin
mutant protein, or to TT, tetanus toxoid, as protein carrier. They
were received as bulk conjugates and were stored frozen at 20 C
or at 4 C, according to the manufacturers' recommendations. Hib-
CRM197 and MenC-CRM197 were supplied from the same manu-
facturer (and correspond to Hib-CRM197-B from Ref. [39] and
MenC-CRM197-A from Ref. [40]). Hib-TT corresponds to Hib-TT-B
from Ref. [41]. Vaccine types used in the study are indicated in
Table 1.
Both Hib bulk conjugates and MenC-CRM197 were extensively
dialyzed at 4 C with three changes of 154 mM NaCl, pH 6.0e6.4
(saline), using SpectraPor 7 membrane with a designated pore size
of 10 kDa. The bulk vaccine MenC-TT was supplied in saline.
The corresponding carrier proteins, CRM197, stored at 20 C, and
TT, stored at 4 C, were obtained from the manufacturers of the cor-
responding conjugates and were also dialyzed in saline. The Hib poly-
ribosyl ribitol phosphate (PRP) polysaccharide used was theWHO 1st
International Standard (NIBSC, 02/208) [42]. MenC a2-9-linked poly-
sialic acid was that routinely used as an in-house reference prepara-
tion for the quantitation of MenC PS. PS stock solutions (10 mg/ml)
were stored frozen at 20 C and were diluted in the appropriate
buffers prior to use.
Final ﬁll MenC-CRM197 from two manufacturers and Hib-TT and
MenC-TTmonovalent vaccineswere also used andwere stored at 4 C.
Diphtheria-Tetanus-Whole-cell pertussis (DTwP)-Hib combination
vaccines from four manufacturers containing 0.06e2.5 mg Al3þ/ml as
AlPO4 were stored at 4 C.
PS concentrations of the bulk conjugates prior to adsorption
were calculated based on the PS/protein ratios supplied by the
manufacturers and determined protein concentrations (see section
R.B.D. Otto et al. / Biologicals 43 (2015) 355e362 3572.4). The content of the PS stocks were determined from their dry
weights.
2.2. Adjuvant adsorption and separation
Prior to adsorption to adjuvant, the bulk conjugates in saline
were diluted in a 2 x stock saline-based buffer or solution to give a
concentration of 40 mg saccharide/ml. These samples were then
mixed with an equal volume of 2 mg/ml adjuvant to achieve
20 mg saccharide/ml and adjuvant at 1 mg/ml, similar to that found
in the ﬁnal products unless quoted. The ﬁnal buffer concentrations
used for adsorption study were 5 mM sodium phosphate, pH 7.2;
50mM sodium phosphate,154mMNaCl, pH 7.2 (PBS); or, 55mM3-
(N-Morpholino)-propanesulfonic acid, 154 mM NaCl, pH 7.2
(MOPS-saline). Hib-TTwas used additionally in 154mMNaCl. In the
combination vaccine experiments, pre-mixing of the Hib and MenC
conjugates was performed prior to adjuvant adsorption.
The adjuvants used were aluminum hydroxide, Al(OH)3 (sup-
plied by Brennag Biosector as Alhydrogel, 2%) and aluminum
phosphate, AlPO4, which was manufactured by mixing aluminum
chloride with tribasic sodium phosphate [15]. These were stored at
2e8 C as stocks of at least 10 mg/ml. Adjuvants were added to the
vaccine components at room temperature to give 0.1 mg or
1 mg Al3þ/ml of aluminum hydroxide, or 0.1 or 1 mg/ml AlPO4
(equivalent to 0.025 or 0.25 mg Al3þ/ml). Mixing was carried out in
2 ml sterile screw-capped eppendorfs for ~16e18 h on a roller at
room temperature, to give complete adsorption. The concentra-
tions chosen were typical of those in licensed MenC conjugate
vaccines or were 1/10 of that allow for measurement of their partial
binding, as vaccine formulations have been developed that pro-
mote maximal binding.
To determine the % adsorption of the vaccines and components
to adjuvant, the amount of non-adjuvanted PS or protein was
measured. Adsorbed samples were ﬁrst centrifuged at 8500 g in a
table-top microcentrifuge for 15 min at 4 C. Non-adsorbed su-
pernatants were carefully taken up in a pipette to avoid mixing of
the adjuvant-containing pellet and transferred to new eppendorf
tubes, and then re-centrifuged and transferred to minimize any
turbidity due to residual adjuvant, which may interfere with
colorimetry.
Protein and/or PS concentrations in the supernatants and in
control samples without adjuvant were analyzed immediately, or
following storage of the samples at 4 C for up to 1 week. The %
recovered non-adsorbed protein and/or saccharide were expressed
relative to controls without adjuvant, as % Adsorbed ¼ 100%  %
Non-adsorbed.
2.3. Saccharide determination
The concentration of non-adsorbedHib PRP PS in the supernatants
was determined using the orcinol assay according to Kabat andMayer
[43], with slight modiﬁcations. Standards were prepared in triplicate
and samples were prepared in duplicate or triplicate to a volume of
500 mL in glass vials in the same buffer as with the standards. Re-
agents were added and well mixed after each addition as follows:
500 mL FeCl3 (1.8 mM in 36% HCl), followed by 50 mL of an orcinol
solution (693 mM orcinol in 100% ethanol). Vials were closed with
Teﬂon seals and incubated for 20 min at 100 C in a heating block.
Samples were equilibrated to room temperature prior to measuring
their absorbance at 670 nm, using a Perkin Elmer Lambda 800
UVeVis spectrophotometer. Ribose standards (Sigma R7500) or
samples containing between 1 and 25 mg/ml ribose gave A670 nm
values of ~0.1e0.8. Ribose concentrations (in mg/ml) were converted
to PRP concentrations bymultiplying by a conversion factor of 2.448 g
PRP/g ribose [42]. The combined standard uncertainty for the orcinolassay was determined to be 3.3%, based on between assay variability
of 2.3% for each determination.
Hib PRP saccharide not bound to aluminum phosphate adjuvant
was also measured by the HPAEC-PAD method developed for DPT
combination vaccines by Bardotti et al. [44]. Manufacturing lots of
DTwPeHib ± HepB were mixed at room temperature with 1 M
sodium phosphate, pH 6.8 and 1 M NaCl to a ﬁnal concentration of
10 mM sodium phosphate, pH 6.8, 50 mM NaCl for 1 h, and
centrifuged for 30 min at 18,400 g. These ‘10 mM desorbed’
supernatants were used for the quantiﬁcation of PRP content,
relative to untreated, samples, which were not desorbed or spun.
Standards (0.5e27 mg PRP/ml) were prepared using the 1st WHO
International Standard for Hib polysaccharide (NIBSC code 02/208).
Samples and standards were hydrolyzed in 0.3 M HCl at 100 C for
2 h, and after cooling, were neutralized with 0.3 M NaOH and
ﬁltered using a 100 kDa MWCOMicrocon ultraﬁlter. An injection of
100 ml of ﬁtrate was made onto the CarboPac MA-1 analytical col-
umn in combination with a MA-1 guard column and the samples
were eluted with 580 mM NaOH for 35 min, with a 1 M NaOH
column re-generation step between samples, if required. A com-
bined standard uncertainty of 10.2% for the HPAEC-PAD assay on
combination vaccines was derived from inter-assay variability of
2.2% for the desorbed sample and 10.6% for the untreated samples.
MenC-containing samples were analyzed for N-acetyl neu-
raminic acid, or NANA, using a resorcinol assay based on the
method of Svennerholm [45]. To 500 mL standard or sample, 500 mL
of the resorcinol-CuSO4-HCl reagent (containing 18.2 mM resor-
cinol, 0.4 mM CuSO4 in 30% HCl) was added and well mixed. The
glass vials were sealed with Teﬂon seals and incubated at 110 C for
15 min in a heating block. Absorbance at 564 nm was read. A
standard curve of 1e30 mg/ml NANA (Sigma A-2388) gave A564 nm in
the range of 0.02e0.45. The average absorbance of the blank was
subtracted from all standards and samples. The combined standard
uncertainty for the resorcinol-determined values was determined
to be 7.5%, based on an intermediate precision of 5.3% for each
determination.
The addition of 6.4e8 mM NaOH to the sample prior to orcinol
or resorcinol-acid reagent was initially performed to aid in the
dissolution of the aluminum adjuvant, but this was later deemed to
be unnecessary. It was also found that the presence of non-speciﬁc
formulation sugars use in the vaccine samples, that is non-pentose
or -sialic acid e containing sugars, did not interfere with the
determination of the PRP or NANA, respectively. Likewise, there
was no apparent interference from the other speciﬁc saccharide
(Hib orMenC) during analysis of the combination vaccine mixtures.
2.4. Protein determination
Protein concentrations were determined by UV spectroscopy
(A280 nmeA450 nm) using a PerkineElmer Lambda 800 UVeVis
spectrophotometer. The following molar absorption coefﬁcients:
A280, 0.1% ¼ 1.229 cm1 mg1 ml for TT (based on amino acid con-
tent) and 0.757 cm1 mg1 ml for CRM197 (based on the manu-
facturer's determined value), to determine the mg/ml
concentrations. The lower limit of quantitation was 4 mg/ml TT or
7 mg/ml CRM197. The combined standard uncertainty of measure-
ment of protein concentration in the adjuvant mixtures was
determined to be ±6.6% for TT and 5.4% for CRM197 based on
spectrophotometric accuracy.
2.5. pH determination
A Jenway model 3305 pH meter was calibrated with pH 4, 7 and
10 buffers at room temperature. Samples containing the adsorbed
components or non-adsorbed supernatants were equilibrated to
Table 3
Effect of buffer on the adsorption of conjugates to aluminum adjuvants.
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accurate to ±0.05 pH units.Vaccine Adjuvanta % Adsorptionb,c
Type Mg Al3þ/ml Hib PS MenC PS
A. In PBS buffer
Hib-CRM AlPO4 0.025 2 ± 3
Hib-CRM Al(OH)3 0.1 2 ± 3
Hib-TT AlPO4 0.025 0 ± 3
Hib-TT Al(OH)3 0.1 4 ± 3
MenC-CRM AlPO4 0.025 0 ± 8
MenC-CRM Al(OH)3 0.1 0 ± 8
MenC-TT AlPO4 0.025 0 ± 8
MenC-TT Al(OH)3 0.1 0 ± 8
B. In MOPS-saline Buffer
Hib-CRM AlPO4 0.025 2 ± 3
Hib-CRM Al(OH)3 0.1 88 ± 3
Hib-TT AlPO4 0.025 31 ± 3
Hib-TT Al(OH)3 0.1 94 ± 3
MenC-CRM AlPO4 0.025 11 ± 7
MenC-CRM Al(OH)3 0.1 96 ± 7
MenC-TT AlPO4 0.025 35 ± 5
MenC-TT Al(OH)3 0.1 97 ± 7
C. Combined in MOPS-saline buffer
Hib/MenC-CRM AlPO4 0.025 5 ± 3 19 ± 6
Hib/MenC-CRM Al(OH)3 0.1 75 ± 3 59 ± 4
Hib/MenC-CRM Al(OH)3 1 93 ± 3 100 ± 8
Hib/MenC-TT AlPO4 0.025 26 ± 2 10 ± 7
Hib/MenC-TT Al(OH)3 0.1 84 ± 3 100 ± 8
Hib/MenC-TT Al(OH)3 1 92 ± 3 99 ± 8
a Adjuvants used were AlPO4 at 0.025 (panels AeC), and Al(OH)3 at 0.1 and 1 mg
Al3þ/ml as indicated.
b Buffers used were PBS (50 mM sodium phosphate, 154 mM NaCl, pH 7.2) or
MOPS-saline (55 mM MOPS, 154 NaCl, pH 7.2). In panel (C) conjugates were pre-
mixed prior to adjuvant adsorption. The results from panels AeC were obtained
from three consecutive, single experiments.
c Statistical intervals were calculated with the combined uncertainty on the
determined values.3. Results
3.1. Bulk conjugate adsorption studies
The adsorption of individual or combined Hib-CRM197 and MenC-
CRM197 conjugates to aluminum-containing adjuvants was measured
in 5 mM sodium phosphate, pH 7.2 by measuring the % recovery of
the carrier protein, CRM197, or PS (Hib PRP or MenC polysialic acid)
present in the non-adsorbed supernatant. The vaccine component
concentration was equivalent to that of licensed MenC conjugate
vaccines, while the adjuvant concentrationwas 1/10 that, to be able to
study the effects of buffer salts, and polysaccharide and carrier protein
type on binding. Both CRM197 conjugates were individually shown to
adsorb weakly or not at all to aluminum phosphate (0e11% for Hib-
CRM197 and 0% for MenC-CRM197), and, to bind more tightly to
aluminum hydroxide (88e100% to Hib-CRM197 and 90e100% to
MenC-CRM197) as shown in Table 2. The combination of Hib-CRM197
and MenC-CRM197 did not affect the adsorption of the conjugates to
either of the adjuvants.
A discrepancy of up to 21% was observed between % adsorption
levels determined by protein or saccharide assay, due mainly to
their combined uncertainty of measurement, but in part to the
occasional turbidity of residual adjuvant, which could interfere
with the protein estimations, at ﬁnal ﬁll concentrations. The pH of
the MenC-CRM197 conjugate remained relatively stable (pH 7.0),
but the pH of the Hib-CRM197 in aluminum hydroxide decreased to
pH 6.4 compared to its control or aluminum phosphate solution
(pH 7.0), suggesting that the 5 mM phosphate solution was not
adequately buffered.
Because of the differences observed in the binding of the CRM197
conjugates to the adjuvants in a low ionic strength phosphate
buffer, the inﬂuence of the phosphate ion was studied in an
adequately buffered solution at a physiological saline concentra-
tion. Phosphate ions have been found to have a number of different
effects on adjuvant, such as promoting Ag-adjuvant adsorption,
competing with Ag adsorption by binding, or exchanging ligands
with adjuvant [8,13,14,21,28,46e48].
Hib and MenC PS conjugated to TT were used in addition to the
CRM197 conjugates and were prepared in more strongly buffered
solutions: either PBS (50 mM sodium phosphate, 154 mM NaCl, pH
7.2) or a non-phosphate buffered saline (55 mM MOPS, 154 mMTable 2
Adsorption of Hib- and MenC-CRM197 conjugates to aluminum adjuvant.
Vaccine Adjuvanta pH % Adsorptionb
Protein Hib PS MenC PS
Hib-CRM AlPO4 7.0 11 ± 5 0 ± 3
Hib-CRM Al(OH)3 6.4 88 ± 5 100 ± 3
MenC-CRM AlPO4 7.1 0 ± 5 0 ± 7.5
MenC-CRM Al(OH)3 7.1 100 ± 5 90 ± 7
Combinedc AlPO4 n.d. 0 ± 5 21 ± 2 1 ± 7
Combined Al(OH)3 n.d. 91 ± 5 96 ± 3 78 ± 6
a Conjugates formulated to 20 mg PS/ml and adjuvant at 0.1 mg Al3þ/ml for
Al(OH)3 or 0.025 mg Al3þ/ml for AlPO4 (equivalent to 0.1 mg AlPO4/mL) were
incubated in 5 mM sodium phosphate, pH 7.2 for 16e18 h at room temperature
prior to determining the % of the non-adsorbed protein or polysaccharide compo-
nent remaining in the supernatant.
b Statistical intervals were derived from applying standard combined uncertainty
to the measured values.
c Hib-CRM and MenC-CRMwere premixed prior to adjuvant addition. The results
were obtained from a single experiment.NaCl, pH 7.2) of equivalent ionic strength and pH. The pKa of MOPS
(7.2) allowed for a direct comparison with PBS.
As with the weakly buffered phosphate solution (5 mM sodium
phosphate, pH 7.2), the adsorption of the Hib-CRM197 and MenC-
CRM197 to aluminum phosphate was negligible. In contrast to the
signiﬁcant binding of CRM197 conjugates to aluminum hydroxide at
low phosphate-containing buffer, there was only low binding of
these conjugates to aluminum hydroxide in PBS. Negligible binding
of Hib-TT and MenC-TT conjugates to either adjuvant in full-
strength PBS was also observed (Table 3A).
If MOPS-saline, pH 7.2 was used, measurable adsorption of the
conjugates to the aluminum adjuvants was observed, with higher
adsorption (88e97% adsorption) to aluminum hydroxide than to
aluminum phosphate (up to 31%) as shown in Table 3B.
The pre-mixture of CRM-conjugates or TT-conjugates prior to
adsorption did not alter this binding pattern. Lower adsorption of the
conjugates to aluminum phosphate (5e26%) than to the ‘hydroxide’
form (59e100%) of the adjuvant was observed (Table 3C). It was
notable that at pH 7.2, the TT-conjugated vaccines bound aluminum
adjuvants to a higher degree than did the CRM197 conjugates.
3.2. Individual component adsorption analysis
To explore the basis for the adjuvanteconjugate association, the
adsorption of the individual PS or carrier protein alone (non-con-
jugated) was studied, in addition to bulk conjugate binding to
adjuvant, at ﬁnal vaccine concentrations. Low-to-negligible binding
of the Hib PRP and MenC poly-sialic acid to aluminum phosphate
was seen. In contrast there was high binding of the PS to aluminum
hydroxide (Table 4). There were clear differences between the
carrier proteins in their adjuvant binding properties. CRM197 did
Table 4
Adsorption of individual PS and protein components to aluminum adjuvants.
Component Vaccine type % Adsorptiona to AlPO4 % Adsorption to Al(OH)3
PS PRP 1 98
MenC 6 100
Protein CRM197 0 100
TT 37 100
Conjugatea MenC-CRM 5 100
MenC-TT 50 83
Hib-TT 48 91
a The % adsorption values of the PS and the protein components were calculated
based in the recoveries of the PS and protein in the non-adsorbed supernantants
relative to controls without adjuvant. The individual components and MenC con-
jugates were in MOPS-saline buffer, pH 7.2, while the Hib-TT conjugate was in sa-
line. The adjuvants were at concentrations of 0.25 mg Al3þ/ml for AlPO4 and
1 mg Al3þ/ml for Al(OH)3, typical of ﬁnal product. The concentrations of vaccine
components were close to that expected in the ﬁnal product, with
15e20 mg saccharide/ml and 35e50 mg protein/ml. The % adsorption values for the
conjugates are an average of those determined for the protein and PS moieties.
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aluminum hydroxide. TT bound partially to aluminum phosphate
and completely to aluminum hydroxide.3.3. Comparison of aluminum concentration
The concentrations of the adjuvants used in the binding
studies described in section 3.1 were only one-tenth those used
in commercial vaccines to allow for a comparison of binding at
sub-maximal absorption conditions. Because the Al3þ ion con-
centration in the aluminum phosphate-adsorbed vaccines or
components is much lower than that in the aluminum hydroxide
samples, adsorption was measured over an equivalent Al ion
concentration range.
Fig. 1 shows the adsorption of the MenC-CRM197, MenC-TT and
Hib-TT bulk conjugates to aluminum phosphate and aluminum hy-
droxide in a non-phosphate-containing saline solution at concentra-
tions ranging from 0.06 to 2mg Al3þ/ml. TheMenC-CRM197 showed a
clear difference in binding to aluminum phosphate, with only
20e40% adsorption of the protein component up to 0.5 mg Al3þ/ml,
compared to 100% absorption to aluminum hydroxide at the sameFig. 1. Effect of adjuvant concentration on binding of CRM197 and TT conjugates. The adso
aluminum hydroxide were studied as a function of adjuvant concentration. The % adsorption
relative to controls without adjuvant. The MenC vaccines were in MOPS-saline buffer, pH 7.2
represent the combined standard uncertainty.concentration (panel A). A differential in the adsorption of the
two aluminum salts to TT conjugates was not as obvious. It was
notable that although the adsorption of both of the TT conjugates
(panel B) was titratable at lower concentrations, their adsorption
was always greater than 20% even at the lowest concentration
used (0.125 mg Al3þ/ml).
As the binding of conjugates to aluminum phosphate at the pH
of this study is mainly through the protein rather than PS moiety,
the amount of protein bound/0.5 mg Al3þwas calculated. For MenC
conjugates, 8.4 mg CRM197 adsorbed to 0.5 mg Al3þ in aluminum
phosphate compared with 21.5 mg CRM197 adsorbed to the same
amount of Al3þ in aluminum hydroxide, showing the higher
strength of binding of aluminum hydroxide to CRM197.
3.4. Adsorption in monovalent MenC conjugate vaccines
The adsorption of three ﬁnal ﬁll monovalent MenC conjugate
vaccines from different manufacturers were measured in their own
formulations after storage for 1 month at 4 C and 37 C. MenC-
CRM197 A was lyophilized in a sodium phosphate buffered solution
with mannitol. MenC-CRM197 B and MenC-TT were in saline for-
mulations. All three vaccines were found to be >98% adsorbed to
their adjuvant whether measured by PS or protein found in the
non-adsorbed supernatant (Table 5). Compared with the minimal
binding of conjugates to aluminum phosphate at pH 7.2, the low
pH saline formulation of (pH 6.1) MenC-CRM197 B, appeared to
promote adsorption. After 1 month at 37 C, the adsorption
remained at 100%. The pHs of the MenC-CRM197 vaccines were
stable, but the pH of the MenC-TT had decreased by 1 pH unit.
Although in an unbuffered saline formulation, it remained within
speciﬁcation; long-term stability studies have also demonstrated
its stability in Al(OH)3 [49,50].
3.5. Effect of carrier protein on adsorption of Hib conjugate in
combination vaccines
The adsorption of the Hib component of DTwP combination
vaccines was evaluated for two CRM197 and TT-based conjugates
in aluminum phosphate formulations, pH 6.0e6.5. There was
considerable adsorption of the TT-conjugates to adjuvantrption of (A) MenC-CRM197 and (B) Hib-TT and MenC-TT to aluminum phosphate and
was calculated by measuring the recovery of non-adsorbed protein in the supernatant,
and the Hib-TT was in saline. The target concentration was 20 mg PS/ml. The error bars
Table 5
Adjuvant adsorption of licensed monovalent MenC conjugate vaccines.
Vaccinea Adjuvant [Adjuvant]
mg Al3þ/ml
%
Adsorptionb
pH
4 C 37 C 4 C 37 C
MenC-CRM-A Al(OH)3 0.7 99 100 7.2 7.2
MenC-CRM-B AlPO4 0.25 98 98 6.1 6.1
MenC-TT Al(OH)3 1 100 100 6.9 5.8
a Commercial monovalent MenC conjugate vaccines were used with their
formulated adjuvants. The vaccines were incubated at the indicated temperature for
1 month prior to the measurement of their adjuvant adsorption.
b Values given for % adsorption to adjuvant were arithmetic averages from the
individual adsorptions of the corresponding protein and saccharide components.
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vaccine C (Fig. 2). Saydam et al. also found variable adsorption of
similar vaccines by ELISA [51]. Only slight adsorption (up to 10%)
of the CRM197-conjugates was found.Fig. 2. Adsorption of Hib conjugate in DTwP-combination vaccines. The adsorption of
Hib conjugates to aluminum phosphate in DTwP combination vaccines was measured
in TT conjugates (C and D series), and CRM197 conjugates (E and F series). The numeral
in the code represents different manufacturing lots of the same vaccine. The %
adsorbed values were determined from measure of PRP remaining in the supernatant
of spun-desorbed samples relative to that in untreated vaccine. The error bars repre-
sent the combined standard uncertainty of the assay.4. Discussion
A clear pattern of adsorption of the highly negatively-charged Hib
and MenC conjugate vaccines to aluminum adjuvant was observed in
this study. At pH 7.0e7.2, aluminum hydroxide is positively charged
(pI¼ 7.4 to 11.4) [6,10] and bound the carrier proteins, tetanus toxoid
(pI≪ 5.95) and CRM197 (pI¼ 5.85) [31,52] and the anionic capsular PS
of Hib (poly-ribosylribitol phosphate) and serogroup C meningo-
coccus (partially O-acetylated or completely de-O-acetylated poly-
sialic acid) more avidly and to a higher degree than did aluminum
phosphate (pI y 4) [12]. The binding of the PS-TT conjugates to
aluminum phosphate adjuvant was primarily facilitated through the
carrier protein rather than through the oligo- or polysaccharide at
neutral pH. The patterns of adsorption were predominated by elec-
trostatic interactions, in line with that observed from model protein
systems [12,53].
Besides the charge of the adjuvant, a second factor favoring the
relatively higher binding of the conjugates to the aluminum hy-
droxide could have been the higher Al3þ concentration of aluminum
hydroxide used in with conjugate vaccines, as compared with
aluminum phosphate (Table 1). Since the binding or adsorption of
protein Ags to aluminum adjuvants occurs principally through elec-
trostatic interactions involving Al3þ metal coordination, this could
explain the higher adsorption of aluminum hydroxide to the vaccine
conjugates at vaccine relevant concentrations. For both CRM197 and
TT-conjugates, it was clear, however, that at equimolar amounts of
aluminum ion, a higher amount of conjugate is bound to aluminum
hydroxide than to aluminum phosphate at pH 7.2.
A third factor, speciﬁc to Hib, is the presence of phosphoryl
groups on the repeating units, which could potentially repel the
phosphorylated adjuvant.
On this basis, other saccharide-based conjugate vaccines, uti-
lizing negatively-charged PS, such as meningococcal serogroups A,
B, W, X and Y; pneumococcal serotypes 1, 6A, 6B, 18C, 19A, 19F and
23F; and, Group B Streptococci type III would be expected to have
similar adjuvant binding behavior under similar conditions, pro-
vided similarly-charged carrier proteins were used.
With respect to the contribution of the carrier proteins,
Coombes et al. [54,59] reported near-complete binding of diph-
theria toxoid (DT) (pI y 4.1e4.6 [55]) and TT, to aluminum hy-
droxide in combination vaccines at neutral pH; lesser adsorption to
aluminum phosphate was found, corroborating the results found
here. In a separate study, higher adsorption of DT to aluminum
phosphate was found to be possible through lowering the pH [56],as was also borne out with MenC-CRM197 B in its own vaccine
formulation (Table 5).
The notable higher binding of the TTcarrier protein compared to
CRM197 to aluminum adjuvant from the composite or combination
vaccines cannot be explained on the basis of isoelectric point alone.
They bind to the adjuvants with different adsorption mechanisms;
being different in structure, with unique surface side-chain charge
densities, hydrophobic regions and hydrogen bonding propensity.
Current methodological approaches that rely on the measurement
of conjugate vaccine potency from non-adsorbed supernatants,
assuming equal interactions for CRM197 and TT conjugates, could
givemisleading results, and product-speciﬁc approaches need to be
considered [51].
Charged excipients also play a role in adjuvant binding patterns.
As the ionic strength of the buffer increases so too does the likeli-
hood of the interference with the surface charges of the species in
the medium, as also explored by others [47,57,58]. In this study,
phosphate ions inhibited the binding of all four types of conjugates
to both adjuvants. As little as 5 mM phosphate, 0.9% NaCl, pH 7.4
has been observed to reduce adsorption of proteins to aluminum
adjuvants [46]. Similar inhibition has been observed for diphtheria
and tetanus toxoids in combination vaccines [48] and with a
monovalent MenC-TT [50] or MenA-TT vaccine (Tiengwe, Mattick&
Bolgiano, unpublished). With a higher strength PBS buffer, con-
taining 10 times more phosphate ion, negligible binding to the
adjuvants was found irrespective of the aluminum salt used.
Opposite charge-effects have been found when using basic
proteins, such as the Hc domain of botulinum toxins, as would be
predicted [47], and in formulations dominated by the low pH of
aluminum phosphate, therewas a lack of effect of phosphate on the
adsorption of pneumococcal 9 V which was 94% bound to adjuvant
[15]. Hem & HogenEsch have described the competing (and
sometimes enhancing) effects from phosphate as due to ligand
exchange or substitutionwith hydroxyl groups at the surface of the
adjuvant [6].
The predominantly charged nature of these interactions means
that vaccine formulation studies, involving pH, ionic strength and
type of buffer salt can be used to ﬁne-tune the adsorption and
amount of aluminum required. By changing only the buffer anion,
variations in adsorption, particularly for aluminum phosphate, can
be achieved. It is interesting to note that all three licensed mono-
valent MenC conjugate vaccines used in this study were completely
bound to adjuvant, including that of a MenC-CRM197 B to aluminum
phosphate at its lowered isoelectric point in unbuffered saline.
Phosphate ions, pH and elevated temperatures are often, utilized in
R.B.D. Otto et al. / Biologicals 43 (2015) 355e362 361‘desorption’ protocols [7,14,41,49,54] and factors affecting adsorp-
tion are also thought to affect the natural elution of Ags from ad-
juvants post-administration.
In this study, the vaccine components in the non-adsorbed fraction
were measured by spectrophotometry and anion-exchange chroma-
tography. The protein assay was the least sensitive and most variable,
and measured protein adsorption was often lower than poly-
saccharide adsorption, also seen by the manufacturer of a MenC-TT
vaccine [50]. ELISA assays for carrier protein [54,59] or PS [50,51],
which was used directly on the adjuvant-precipitate, offer other al-
ternatives, as does HPAEC-PAD [44,60].
The stability of vaccines adsorbed to adjuvant depends on consis-
tent manufacturing, and stable adjuvant-Ag interaction throughout
shelf-life, formulation and storage temperature [22,30,61e63], avoid-
ingeffectsas seenwithmetal ion-catalyzeddepolymerisationofHibPS
arising from an aluminum adjuvant [29] or possible Ag-adjuvant
displacement. The possibility of Ag desorption from adjuvant could
conceivably occur, for example, following depolymerization of the
labile phosphodiester bonds in Hib, MenA, MenX, and Pneumo types
6B, 18C, 19F and 23F, from the formation of phosphate ions. In this
study, therewasnoevidenceof aphysical interactionbetweenHiband
MenC conjugates when combined adding to previous ﬁndings from a
size-exclusion chromatography study of CRM197 conjugates [64]. The
stability of the adsorption of three licensed MenC conjugates in this
study was demonstrated at 4 C and 37 C for one month.
Because the effect of adjuvants are demonstrated during the non-
clinical evaluation of vaccines [23], there are fewpublished examples
that link adjuvant adsorption, composition or dose with clinical
immunogenicity, efﬁcacy or reactogenicity in humans [65e67]. Prior
to the introduction of a booster dose of conjugate vaccines at 12mo in
the U.K., the effect of combining Hib conjugates with diphtheria-
tetanus-acellular pertussis vaccines gave lower than expected
immunogenicity and protection due to lower antibody quality
[34,35]. Speciﬁc adjuvant adsorption to the Hib component has been
considered as a possible cause [68]. However, a separate clinical
study of Hib-CRM197 conjugates in phosphate buffered saline and
equivalent aluminum and Ag dose levels administered to infants
with DTaP vaccine, showed no signiﬁcant difference in anti-PRP re-
sponses [65]. Despite some clinical and post-marketing ﬁndings of
potential interference in the immunogenicity and protection from
conjugate vaccines, immunization programs depend on the co-
administration and combination of a large number of pediatric vac-
cines. Complex vaccine formulations should be optimized in terms of
stability of adsorption, andAg-adjuvant dose tomaximize the beneﬁt
of saccharide-protein conjugate components when aluminum ad-
juvants are necessary.
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